McClellan to Congress: Benefits of Genomics Outweigh Increased Healthcare Costs | GenomeWeb

NEW YORK, July 14 - In testimony before the Joint Economic Committee of the US Congress last week, FDA Commissioner Mark McClellan warned that innovative biomedical technologies such as genomics, proteomics, and bioinformatics may lead to an increase in the overall costs of healthcare, but noted that "the potential benefits of new treatments could grow even more dramatically."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.